Zeiss partners with Molecular Imaging Platform at McGill University Health Centre
Zeiss has entered into a partnership with the Research Institute of the McGill University Health Centre's Molecular Imaging Platform.
Zeiss (North York, ON, Canada) has entered into a partnership with the Research Institute of the McGill University Health Centre (RI-MUHC)'s Molecular Imaging Platform, its core research imaging facility. The platform provides researchers with access to Zeiss imaging systems customized for a variety of applications. New equipment includes an ELYRA PS.1 super-resolution microscopy combi-system with LSM 880, two multiphoton LSM microscopes, and a Cell Observer SD spinning disk confocal microscope. Purchased with funds from the Canada Foundation for Innovation and the ministère de Santé et des Services sociaux du Québec, these instruments will allow the platform to offer users a broad range of high-end imaging modalities.
The ELYRA PS.1 super-resolution microscope is configured with photoactivated localization microscopy (PALM), structured illumination microscopy (SIM), and laser scanning spectral confocal (LSM) modalities, which will allow visualization of structures down to 10 nm. Cell Observer SD is capable of high-speed optical sectioning. Ideal for examination of subcellular dynamics, the microscope is equipped with a Yokogawa CSU-X1 and two EMCCD cameras for high-sensitivity, dual-channel imaging. The system also offers total internal reflection fluorescence (TIRF) microscopy and fluorescence recovery after bleaching (FRAP) with live cell specimens. Additional LSM multiphoton microscopy systems allow for deep-tissue animal imaging with both MPX and OPO capabilities for extended infrared (IR) wavelength and dual-beam excitation for multimodal imaging, combined with a high-sensitivity spectral confocal scanner with a 32 GaAsP detector that allows separation of up to 10 channels in one scan.
For more information, please visit www.zeiss.com.
Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn